We found the HAVCR1 overexpressed in tumor tissue and participated in the immune response, which could be a potential tumor immunotherapy target, such as PD1, PDL1, CTLA4, p53, etc (Chasov et al., 2021; Jin et al., 2022). Here, HAVCR1 is linked to neoplasm.